Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604875 | 0.89 | VDR (0.45) | VDRKMT2APPARGPPARAALDH1A1 | |
| SCHEMBL2856534 | 0.84 | VDR (0.42) | VDRKMT2APPARGPPARAALDH1A1 | |
| SCHEMBL1022007 | 0.83 | ALDH1A1 (0.42) | VDRPPARGPPARAALDH1A1HPGD | |
| SCHEMBL2863404 | 0.80 | VDR (0.68) | VDRKMT2APPARGPPARAALDH1A1 | |
| SCHEMBL2857757 | 0.76 | SRD5A2 (0.39) | KMT2AALDH1A1HPGDMEN1 | |
| SCHEMBL2856601 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HPGD | |
| SCHEMBL7173547 | 0.73 | ALDH1A1 (0.69) | MTNR1AKMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL31427513 | 0.73 | ALDH1A1 (0.69) | MTNR1AKMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL2853381 | 0.72 | VDR (0.58) | VDRKMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL2855027 | 0.71 | HTT (0.41) | VDRPPARGPPARAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814847-B1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RES & DEV (FR) | 2011-01-12 | — | — | EP | claimed |
| US-7638657-B2 | Preparation of 3-[5′-(3,4-bis(hydroxymethyl)benzyloxy)-2′-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-29 | — | — | US | claimed |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-06 | — | — | US | claimed |
| EP-1814847-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | Galderma Research & Development (FR) | 2007-08-08 | — | — | EP | claimed |
| WO-2006053985-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | claimed |
| EP-1814847-B1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RES & DEV (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7638657-B2 | Preparation of 3-[5′-(3,4-bis(hydroxymethyl)benzyloxy)-2′-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-29 | — | — | US | disclosed |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-06 | — | — | US | disclosed |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-06 | — | — | US | disclosed |
| EP-1814847-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | Galderma Research & Development (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053985-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | PARP2, CYP4B1, CYP8B1 | MTNR1A 4274/4885VDR 591/4885KMT2A 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.